The present decision goes back to the 2d quarter of 2023. Its importance came to light when it was commented recently in “Le blog du droit européen des brevets”. .
The patent relates to a botulinum toxin assay with improved sensitivity.
Brief outline of the procedure
Claim 1 and 9 as granted were considered lacking sufficiency by the OD.